Continuing Education Activity

Tretinoin is a valuable medication with diverse clinical applications, including the treatment of mild, moderate, and severe acne as well as the systemic management of acute promyelocytic leukemia. As a vitamin A derivative in the retinoid class, tretinoin functions by modulating epithelial cell differentiation, reducing comedone formation, and promoting turnover of skin cells. This activity outlines the indications, actions, and contraindications of tretinoin, emphasizing its role in the management of acne vulgaris and acute promyelocytic leukemia. It highlights key factors, including the mechanism of action, adverse event profile, and off-label uses, such as the treatment of pre-malignant and malignant skin conditions, psoriasis, and other common dermatologic disorders. Additionally, the course reviews dosing strategies for both oral and topical formulations, as well as monitoring requirements, including the importance of reliable contraception during systemic therapy, to ensure the safe and effective use of these medications.

Participants completing this course gain a comprehensive understanding of tretinoin’s therapeutic roles and its safe administration in various patient populations. They learn to evaluate treatment options for acne and acute promyelocytic leukemia, integrate knowledge of adverse effects, and consider patient-specific factors that influence dosing and monitoring. The activity highlights the importance of collaboration within an interprofessional team, comprising physicians, pharmacists, and nurses, in optimizing patient outcomes. Coordinated care ensures accurate administration, monitoring for adverse events, and patient education regarding safety measures such as contraception for systemic use. By leveraging the expertise of multiple healthcare professionals, participants recognize how interprofessional collaboration improves adherence, enhances treatment efficacy, and reduces complications in patients receiving tretinoin for both dermatologic and oncologic indications.

Objectives:

• Asserss the importance of monitoring for patients on tretinoin therapy, including target triglyceride and liver function concentrations.
• Identify the risks associated with initiating tretinoin treatment along with key patient counseling points.
• Identify the most common adverse events associated with tretinoin treatment.
• Outline the importance of how collaboration and coordination among the interprofessional team can enhance patient care when dosing and monitoring tretinoin to improve patient outcomes for patients receiving topical (anti-acne and palliative for photoaging) and oral (antineoplastic) tretinoin.

Access free multiple choice questions on this topic.

Indications

Tretinoin is a generic name for a medication derivative of vitamin A (retinol), also commonly known as all-trans retinoic acid (ATRA). Tretinoin can be given systemically or topically for various indications.

FDA Indications for Use of Tretinoin

Topical Tretinoin

Topical formulations of tretinoin, including gels and creams, are FDA-approved for several dermatologic indications. The primary indication is the treatment of acne vulgaris, where topical tretinoin acts to normalize follicular epithelial differentiation, reduce the formation of comedones, and decrease inflammation in affected skin.[1] In addition to its use for acne, topical tretinoin is approved as an adjunctive palliative treatment for signs of photoaging. Specifically, it has been shown to improve fine facial wrinkles, reduce facial skin roughness, and treat facial mottled hyperpigmentation, commonly referred to as “liver spots”.[2]

Oral Tretinoin

Oral tretinoin is FDA-approved for the treatment of acute promyelocytic leukemia (APL) under several specific conditions. It is indicated for patients with refractory disease requiring remission induction who have previously relapsed after anthracycline chemotherapy, as well as for those with contraindications to anthracycline-based therapy.[3] Oral tretinoin is particularly recommended for patients whose leukemia exhibits chromosomal translocations between chromosomes 15 and 17, t(15;17), consistent with the French-American-British classification M3, including the M3 variant.[4] Furthermore, it is indicated for patients whose disease demonstrates the presence of the PML/RARα gene and who are either refractory to or have relapsed after anthracycline chemotherapy, or who cannot receive anthracyclines due to contraindications.[5][6] In addition to its oncologic applications, oral tretinoin is also approved for the treatment of moderate to severe acne, including cystic acne, in both adolescents and adults. In this context, tretinoin functions to promote epithelial turnover, prevent the formation of new comedones, and reduce inflammatory lesions, thereby improving overall skin appearance and minimizing the risk of scarring.[7][8][9]

FDA Off-Label Uses of Tretinoin

Tretinoin has several FDA off-label applications that extend beyond its approved uses in acne, photoaging, and APL. In patients with APL, tretinoin may be used during the consolidation phase of treatment in combination with chemotherapy.[10][11] Evidence supports its use in adults with APL alongside arsenic trioxide, highlighting its role as a component of consolidation therapy following initial induction.[12] Additionally, tretinoin may be used during the maintenance phase of therapy for intermediate- and high-risk adult patients receiving combination chemotherapy.[13][14] Pediatric patients with APL may also benefit from tretinoin as part of maintenance therapy in combination with chemotherapy, supporting its use across age groups in ongoing leukemia management.[15]

Beyond hematologic applications, tretinoin has been explored in the treatment of various pre-malignant and malignant dermatologic conditions, particularly in high-risk patients. This includes actinic keratosis as well as basal and squamous cell carcinomas.[16][17][18][19] Tretinoin has also been utilized in the management of actinic lentigines and chronic dermatologic disorders such as psoriasis.[20][21] Genetic or congenital skin disorders, including ichthyosis congenita, ichthyosis vulgaris, and lamellar ichthyosis, have also been treated with topical tretinoin.[22]

Other dermatologic conditions for which tretinoin has been applied include cutaneous warts—particularly the flat subtype—keratosis follicularis (Darier disease), epidermolytic hyperkeratosis, and other keratinopathic ichthyoses, as well as verruca vulgaris.[23] Some studies also suggest that tretinoin may play a role in the early treatment of stretch marks.[24]

Emerging and Investigational Uses

Several applications of tretinoin are currently under investigation or considered experimental. For example, adult T-cell leukemia/lymphoma has been identified as a potential area for future study regarding the therapeutic role of tretinoin.[25] Additionally, topical tretinoin may enhance hair growth when combined with minoxidil, likely due to increased transdermal penetration, although this effect requires further clinical investigation.[26]

Mechanism of Action

The exact mechanism by which topical tretinoin functions is not completely understood; however, current evidence suggests that it mediates its effects through the binding of retinoic acid receptors (RARs) alpha, beta, and gamma, as well as retinoid X receptors (RXRs), by blocking inflammatory mediators. By doing this, the production of procollagen increases to support the formation of collagen types I and III.[27]

RAR-gamma effects are associated with mucocutaneous tissues and bone. Tretinoin's effectiveness as an acne medication is due to its ability to modify the abnormal follicular formation resulting from excessive keratinization of epithelial cells. Tretinoin promotes the detachment of cornified cells and enhances their shedding. Tretinoin increases mitotic activity, thereby increasing the turnover of loosely adherent corneocytes. By doing so, the comedo contents can be expelled, with a reduction of the microcomedo precursor lesion of acne vulgaris. RAR-alpha and -beta have been associated with APL and squamous cell malignancies, respectively.

Retinoic acid binds to retinoic acid receptor alpha, a member of the steroid-thyroid hormone receptor superfamily. RARα forms heterodimers with RXR and binds to retinoic acid response elements that are present in genes involved in cell differentiation. Again, like topical tretinoin, the exact mechanism of systemic tretinoin is unclear, but is hypothesized to include the following:

1. Apoptosis and degradation of the PML-RARα protein occur through both caspase-mediated cleavage and proteasome-dependent degradation. 
2. PML-RAR alpha conversion from a transcription repressor (CoR) to an activator (CoA).
3. Coordinated gene expression induced by ATRA is committed to the differentiation of APL cells.[28]

Systemic tretinoin produces complete remission by inducing an initial primitive promyelocyte maturation followed by bone marrow and peripheral blood repopulation occurring by normal, polyclonal hematopoietic cells.

Administration

 Topical Tretinoin

Topical tretinoin is most commonly administered as a thin layer applied once daily, preferably in the evening before bedtime, to areas of skin affected by acne lesions. Patients should take care to avoid contact with the eyes, mouth, nasal creases, and all mucous membranes to prevent irritation. Dosages and formulations vary among available products, but commonly prescribed concentrations include 0.1%, 0.08%, and 0.04%. These formulations are designed to be applied sparingly yet evenly, with just enough medication to cover the affected skin surface in a thin, even layer. Patient education should emphasize consistency of use, the expectation of gradual improvement, and the potential for transient irritation during the initiation of therapy.

Oral Tretinoin

In the systemic treatment of APL, oral tretinoin (all-trans retinoic acid, ATRA) should be administered with food, as this enhances absorption. Capsules must be swallowed whole and should not be opened, chewed, or crushed, as this may alter the pharmacokinetics and stability of the drug. Alternative administration routes have been reported in clinical practice, including sublingual administration by squeezing the capsule contents beneath the tongue and delivery through enteric or nasogastric tubes when oral ingestion is not feasible.[29][30][31] ATRA monotherapy, although effective at inducing remission, is associated with relapse within approximately 3.5 months. Therefore, ATRA must always be used in combination with other agents, such as arsenic-based compounds or anthracycline-based chemotherapy, to achieve durable remissions.[32] The recommended systemic dose for APL is 45 mg/m²/day, administered in 2 evenly divided doses, and continued until complete remission is achieved. If a dose is missed, patients should take it as soon as they remember unless it is nearly time for the next scheduled dose; in that case, the missed dose should be skipped. Double-dosing is not recommended, as it increases the risk of toxicity. Breastfeeding is contraindicated during oral tretinoin therapy, as the drug carries the potential for serious adverse effects in nursing infants. Therefore, nursing mothers should discontinue breastfeeding before initiating systemic tretinoin.

Isotretinoin for Acne Treatment

For acne vulgaris, isotretinoin (a systemic retinoid distinct from tretinoin but closely related) should be administered with food, particularly high-fat meals, to maximize bioavailability. Additionally, a lipid-encapsulated isotretinoin formulation is now available, which enhances absorption regardless of food intake and enables consistent dosing, either once or twice daily.[33] Treatment goals are defined by a cumulative dose target, typically between 120 and 150 mg/kg, usually achieved over the course of 20 to 24 weeks of therapy.[34] Standard initiation involves a starting dose of 0.5 mg/kg/day during the first month, which may be escalated to 1 mg/kg/day depending on patient tolerance and clinical response. Doses can be given once daily or divided into 2 administrations per day. Careful dose titration, laboratory monitoring, and patient counseling are essential to maximize therapeutic benefit while mitigating the drug’s well-known toxicities.

Acute Promyelocytic Leukemia Treatment – Adult Patients

Relapsed or refractory APL

For adult patients with relapsed or refractory APL, the recommended oral dosage of tretinoin is 22.5 mg/m² administered twice daily. This regimen is intended for induction therapy, and treatment should generally be discontinued 30 days after achieving remission, although it may be continued for up to 90 days if clinically indicated. Due to the risk of differentiation syndrome—a potentially serious complication characterized by fever, dyspnea, weight gain, and fluid retention—prophylactic measures are recommended for patients presenting with a white blood cell (WBC) count exceeding 10,000/µL.

Newly Diagnosed APL

Induction therapy

In adult patients who are newly diagnosed with APL, induction therapy also involves oral tretinoin at a dosage of 22.5 mg/m² twice daily for a duration of up to 60 days. In patients classified as low-risk—typically those with WBC counts below 10,000/µL—tretinoin is commonly combined with arsenic trioxide to enhance therapeutic efficacy. As with relapsed or refractory cases, differentiation syndrome prophylaxis is advised for patients whose WBC exceeds 10,000/µL.

Consolidation therapy

Following successful induction, consolidation therapy is administered to maintain remission and prevent relapse. The standard regimen consists of tretinoin at 22.5 mg/m² twice daily on days 1 through 14 and again on days 29 through 42 of a 56-day cycle, repeated for 3 consecutive cycles. For the fourth cycle, tretinoin is given on days 1 through 14 of a 56-day cycle. In low-risk adult patients, this consolidation therapy may also be combined with arsenic trioxide to optimize outcomes.

Acute Promyelocytic Leukemia Treatment – Pediatric Patients

Relapsed or refractory APL (1 year of age and older)

For pediatric patients aged 1 year and older with relapsed or refractory APL, the recommended oral tretinoin dosage mirrors the adult regimen at 22.5 mg/m² twice daily. The therapy is intended for induction, with discontinuation 30 days after achieving remission or continuation for up to 90 days if necessary. As in adult patients, concomitant prophylaxis against differentiation syndrome is recommended for children presenting with WBC counts exceeding 10,000/µL.

Adverse Effects

According to the FDA drug labeling guidelines, the most common adverse effects in topically administered tretinoin are the following: pruritus, skin pain, skin/subcutaneous irritation, erythema, and pharyngitis. According to the FDA drug labeling guidelines for orally administered tretinoin, most patients experience drug-related toxicity, such as headaches, weakness, fever, and fatigue. Interruption of therapy is rarely required, as these adverse effects are typically temporary and reversible.

Serious Reactions:

• RA-APL syndrome
• Cardiovascular disorders
• Arrhythmias
• Hypertension
• Pseudotumor cerebri
• Renal tubular necrosis
• Hypercalcemia
• Gastrointestinal disorders
• Pancreatitis
• Hallucinations
• Depression
• Myositis
• Erythema nodosum
• Genital ulcer
• Vision changes
• Hearing loss
• Thrombosis
• Thrombocytosis
• Vasculitis

Common Reactions:

• Headache
• Fever
• Edema
• Bone pain
• Xeroderma
• Dry mucous membranes
• Hyperlipidemia
• Liver function tests are elevated
• Dyspnea
• Nausea/vomiting
• Abdominal distention/pain
• Neurologic disturbances
• Weight changes
• Chest discomfort
• Cardiovascular disorders
• Mucositis
• Vision changes
• GI disorders
• Anxiety/agitation
• RA-APL syndrome
• Otalgia
• Diarrhea
• Arrhythmia
• Flushing
• Pruritus
• Diaphoresis
• Dizziness
• Constipation
• Paresthesia
• Alopecia
• Myalgia
• Hypotension
• Insomnia
• Depression
• Hypertension
• Confusion
• Dysuria
• Fluid imbalance
• Hallucinations
• CNS depression
• Renal tubular necrosis
• Prostate hypertrophy
• Photosensitivity
• Rash
• Ocular abnormalities
• Genital ulceration [35]

Retinoid Toxicity

• Frequently reported adverse effects are most similar to vitamin A toxicity and include the following: headache, nausea/vomiting, bone pain, mucositis, rash, fever, pruritus, skin/mucous membrane dryness, visual disturbances, increased sweating, ocular disorders, alopecia, skin changes, bone inflammation, changed visual acuity,and  visual field defects. Do not administer tretinoin with vitamin A due to symptoms of the syndrome of hypervitaminosis A.
• Pseudotumor cerebri/intracranial hypertension may also occur, especially if given in combination with other medications that increase intracranial hypertension. 

FDA Boxed Warnings 

Retinoic acid–associated acute promyelocytic leukemia syndrome

Retinoic acid–associated acute promyelocytic leukemia (RA-APL) Syndrome is a potentially life-threatening complication characterized by a constellation of clinical signs and systemic manifestations. Patients may present with acute respiratory distress, shortness of breath (dyspnea), fever, and rapid weight gain. Additionally, fluid accumulation can occur in the pleural and pericardial spaces, resulting in pleural and pericardial effusions, as well as generalized edema. Pulmonary infiltrates may be visible on chest radiographs, and in severe cases, the syndrome can progress to multiorgan failure, particularly affecting the kidneys and liver. Cardiac complications are also reported, including impaired myocardial contractility and episodic hypotension, which may occur with or without an accompanying increase in white blood cell count (leukocytosis). If untreated or unrecognized, RA-APL syndrome can result in death, primarily due to progressive hypoxemia and multiorgan failure. Although most cases occur within the first month of treatment with tretinoin, rare instances have been reported following the very first dose. Early recognition and management are critical: patients with any clinical suspicion of RA-APL syndrome should be treated promptly with high-dose corticosteroids to reduce morbidity and mortality associated with the condition.[36]

Leukocytosis and risk management

Patients with elevated baseline WBC counts—specifically, those exceeding 5,000/µL—face a significantly increased risk of severe complications, with up to 40% experiencing devastating outcomes. In these cases, high-dose steroid therapy should be initiated immediately upon suspicion of RA-APL syndrome. Additionally, incorporating chemotherapy may help reduce the incidence of RA-APL syndrome in patients whose WBC counts are either elevated at baseline or demonstrate rapid increases during tretinoin therapy, even in cases where baseline leukopenia is present.[37]

Teratogenicity

Tretinoin is associated with a significant teratogenic risk when administered orally, increasing the likelihood of severe fetal malformations. Therefore, strict precautions are required for women who are pregnant or of childbearing potential. Patients must utilize 2 reliable forms of contraception throughout the duration of tretinoin therapy and continue at least 1 form for 1 month after discontinuation. Before initiating treatment, a negative pregnancy test obtained within 1 week is required. In urgent cases where treatment cannot be delayed, therapy may begin with the 2 forms of contraception in place. Pregnancy testing and counseling on effective contraception should continue monthly during therapy. It should be noted, however, that topical formulations of tretinoin do not carry an FDA boxed warning regarding teratogenicity.[38]

Interaction characteristics:

• CYP3A4 substrate
• Ototoxicity
• Photosensitivity
• Thrombogenic effects

Contraindications

According to FDA-labeled prescribing guidelines, tretinoin carries several important contraindications and safety considerations that must be strictly observed to ensure patient safety. A primary contraindication is the presence of hypersensitivity to tretinoin itself or to any of its formulation components, as administration in such cases may lead to significant allergic reactions.

Pregnancy presents one of the most critical contraindications. Tretinoin is classified as Category C under the U.S. Food and Drug Administration (FDA) and Category D under the Australian Therapeutic Goods Administration, reflecting substantial evidence of teratogenicity. If administered during pregnancy, tretinoin is associated with a markedly increased risk of spontaneous abortion as well as severe congenital malformations. Documented abnormalities include defects of the musculoskeletal system, thymus, central nervous system, external ear, eyes, and great vessels. Additional risks include cleft palate, facial dysmorphia, and parathyroid hormone deficiency, which collectively underscore the high level of fetal vulnerability to retinoid exposure.[36]

For all women of childbearing potential, effective contraception is mandatory throughout the duration of tretinoin therapy and must be continued for at least 1 month after treatment discontinuation. Importantly, this requirement applies even to patients with a history of infertility or menopause, reflecting the high stakes of fetal exposure. Standard recommendations advise the simultaneous use of 2 reliable forms of contraception. Abstinence is considered an acceptable alternative. The only exception is in women who have undergone a hysterectomy, for whom contraception is unnecessary. Should pregnancy occur during treatment despite these precautions, physicians and patients must engage in a careful discussion regarding the risks of continuing versus terminating the pregnancy. From a genetic perspective, tretinoin is specifically indicated for patients with APL harboring the t(15;17) translocation. In the absence of this genetic marker, alternative treatment regimens should be pursued, as tretinoin does not provide therapeutic benefit in these patients.

Additional contraindications include oral tretinoin use during breastfeeding, given the unknown but potentially harmful effects on nursing infants. Use is also contraindicated in pregnancy during the first trimester and requires extreme caution if therapy must continue into the second or third trimester. Similarly, caution is advised when prescribing tretinoin to females of reproductive potential and pediatric patients, as these populations are particularly vulnerable to the drug’s adverse effects. Taken together, these contraindications underscore the importance of rigorous patient screening, counseling, and monitoring before and during tretinoin therapy.

 Topical tretinoin contraindications:

• Hypersensitivity to the drug, drug class, or drug formulation components
• Caution if hypersensitivity to fish products (0.05% gel, 0.05% lotion forms)
• Caution if sunburn
• Caution if photosensitivity
• Caution if eczema
• Caution if pregnancy 1st trimester

Monitoring

Patients diagnosed with APL require close supervision by a physician and a treatment team experienced in managing this specific malignancy. Care should be delivered in a facility equipped with the necessary expertise and supportive services to ensure proper monitoring of drug tolerance, efficacy, and toxicity. This level of oversight is essential because oral tretinoin, a cornerstone of APL therapy, is associated with potentially severe and life-threatening adverse reactions that demand early recognition and intervention. In addition to systemic monitoring for APL, patients using topical formulations of tretinoin should also be observed for localized adverse effects, including hypersensitivity reactions, photosensitivity, and other manifestations of skin irritation or allergic response. Such vigilance helps prevent unnecessary morbidity and supports patient adherence to therapy.

Systemic monitoring in APL extends beyond efficacy assessments to include surveillance for treatment-related complications. Patients should be carefully evaluated for clinical response to therapy as well as for serious adverse events, particularly RA-APL syndrome and leukocytosis. RA-APL syndrome can rapidly progress to respiratory failure and multi-organ dysfunction if unrecognized, highlighting the importance of ongoing assessment throughout treatment.

Routine follow-up is also a critical component of safe tretinoin therapy. Monthly clinic visits are required to ensure comprehensive monitoring. Laboratory evaluation should include a complete blood count with differential, lipid panel, liver function tests, and coagulation studies such as PT/INR. In patients at risk for lipid abnormalities, fasting triglyceride levels should be assessed weekly to biweekly to evaluate treatment-related dyslipidemia, though the frequency of monitoring should be tailored to the patient’s baseline health status. Young, otherwise healthy individuals without personal or strong family histories of dyslipidemia or diabetes mellitus may require less frequent laboratory surveillance compared to higher-risk patients.[39] This structured and multidisciplinary approach to monitoring not only enhances patient safety but also supports timely interventions that improve treatment outcomes in APL while minimizing risks associated with both systemic and topical tretinoin use.

Clinical assessment of the following areas is necessary to assess for treatment response and adverse effects:

• Perceived worsening/improvement of acne
• Muscle or bone pain
• Dryness of skin or mucous membranes
• Headaches
• Mood changes, depression symptoms, or suicidality
• Nosebleeds
• Vision changes
• Abdominal pain
• Bowel symptoms

For women of childbearing age, strict precautions are required when initiating and continuing tretinoin therapy due to its known teratogenic effects. Participation in the iPLEDGE program is mandated to minimize the risk of fetal exposure, which typically involves monthly follow-up visits to ensure compliance with pregnancy prevention requirements. Before beginning therapy, a serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL must be obtained within 1 week of treatment initiation, and treatment should be delayed until a negative result is confirmed. Throughout therapy, women of childbearing potential are advised to consistently use 2 reliable forms of contraception during treatment and for at least 1 month following discontinuation. Pregnancy monitoring and contraception counseling are repeated monthly to reinforce adherence. In situations where therapy cannot be delayed, such as in the urgent treatment of APL, initiation may proceed provided that 2 dependable forms of contraception are used concurrently.

Toxicity

Overdose with tretinoin can present with a range of symptoms depending on the route of administration. In topical use, signs of overdose are typically localized and may include excessive redness, peeling of the skin, and significant discomfort. Oral overdose, however, is associated with more systemic effects and may manifest as cracked and sore lips, generalized redness, headache, flushing, abdominal pain, dizziness, and impaired coordination. A case report describes a 39-year-old individual who ingested approximately 1000 mg of tretinoin in a suicide attempt; interestingly, the only clinical consequence was self-limited, non-bloody diarrhea, which was successfully managed with hydration and activated charcoal therapy.[40]

In the context of isotretinoin therapy for acne, metabolic monitoring is particularly important due to its effects on lipid metabolism. Elevations in triglyceride concentrations to mild or moderate levels (300–500 mg/dL) generally do not require discontinuation or dose adjustment; instead, they are managed through dietary and lifestyle modifications. More severe elevations (500–800 mg/dL) may necessitate a reduction in isotretinoin dosage and the initiation of a lipid-lowering agent. If triglycerides exceed 800 mg/dL, cessation of isotretinoin is strongly recommended due to the increased risk of acute pancreatitis.[41][42] Importantly, discontinuation of isotretinoin typically results in normalization of triglyceride concentrations. Hepatic function must also be closely monitored during therapy. If liver enzyme levels increase to more than 3 times their baseline values, the recommendation is to discontinue isotretinoin to prevent further hepatotoxicity. Unlike certain other systemic agents, tretinoin may be discontinued abruptly without the need for tapering.

Enhancing Healthcare Team Outcomes

All-trans retinoic acid (ATRA) therapy should be initiated immediately once APL is suspected, as early treatment has been shown to improve outcomes significantly. If diagnostic confirmation with genetic or molecular testing does not support APL, then ATRA must be discontinued. Management decisions also depend on the patient’s WBC count at the time of presentation. In patients with a low WBC count (≤10 × 10⁹/L), the use of additional antileukemic agents or chemotherapy may be postponed until molecular confirmation of APL is obtained. However, in patients presenting with leukocytosis (>10 × 10⁹/L), chemotherapy should begin without delay, even while awaiting definitive diagnostic confirmation, due to the higher risk of disease complications.[5]

Before prescribing tretinoin, pregnancy status must be confirmed as negative with a urine pregnancy test, reflecting both standard clinical practice and regulatory requirements. This precaution is necessary due to the well-documented teratogenicity of tretinoin, which is associated with severe fetal malformations and risk of fetal loss. Because the excretion of oral tretinoin in breast milk remains unknown, breastfeeding is strongly discouraged in patients undergoing therapy, given the possibility of serious adverse effects in nursing infants.

A serious but unpredictable complication of ATRA therapy is RA-APL syndrome, also known as differentiation syndrome. Clinical signs can include dyspnea, fever, rapid weight gain, pleural or pericardial effusions, acute respiratory distress, pulmonary infiltrates observable on chest radiographs, generalized edema, and progression to multi-organ failure. Prompt recognition and intervention are critical; however, once the syndrome has resolved with supportive treatment, ATRA therapy can be safely resumed.[43]

Patients on tretinoin should be counseled extensively on sun protection due to increased photosensitivity associated with therapy. The use of sunscreen with a minimum SPF of 15, protective clothing, and avoidance of both direct sunlight and artificial tanning beds are strongly recommended. These measures should be followed consistently, including on cloudy days, as harmful ultraviolet radiation still penetrates cloud cover. In addition, patients should be advised to avoid topical products that may exacerbate irritation or dryness, such as harsh soaps, chemical hair treatments, alcohol-containing skin products, astringents, or preparations containing lime, spices, or other irritating agents.

Finally, optimal outcomes in tretinoin therapy depend on coordinated interprofessional care. Physicians, nurses, pharmacists, and other healthcare professionals must work together to ensure comprehensive patient education, close monitoring for complications, and the safe administration of therapy. This team-based approach helps maximize therapeutic benefit while minimizing risks associated with tretinoin and ATRA use.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Rathi SK. Acne vulgaris treatment : the current scenario. Indian J Dermatol. 2011 Jan;56(1):7-13. [PMC free article: PMC3088940] [PubMed: 21572783]

2.

Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-48. [PMC free article: PMC2699641] [PubMed: 18046911]

3.

Damery E, Solimando DA, Waddell JA. Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hosp Pharm. 2016 Sep;51(8):628-632. [PMC free article: PMC5030872] [PubMed: 27698500]

4.

Chen Z, Wang Y, Wang W, Gong J, Xue Y. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype. Chin Med J (Engl). 2002 Jan;115(1):58-61. [PubMed: 11930660]

5.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-1643. [PMC free article: PMC6509567] [PubMed: 30803991]

6.

McCulloch D, Brown C, Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther. 2017;10:1585-1601. [PMC free article: PMC5359123] [PubMed: 28352191]

7.

DiGiovanna JJ, Peck GL. Oral synthetic retinoid treatment in children. Pediatr Dermatol. 1983 Jul;1(1):77-88. [PubMed: 6238291]

8.

Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009 May;1(3):162-9. [PMC free article: PMC2835909] [PubMed: 20436884]

9.

Leyden JJ, Del Rosso JQ, Baum EW. The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. J Clin Aesthet Dermatol. 2014 Feb;7(2 Suppl):S3-S21. [PMC free article: PMC3970835] [PubMed: 24688620]

10.

Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F., Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 28;116(17):3171-9. [PubMed: 20644121]

11.

Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B., PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. [PubMed: 20393132]

12.

Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01;27(4):504-10. [PMC free article: PMC4881307] [PubMed: 19075265]

13.

Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P., Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. [PubMed: 14576047]

14.

Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. [PMC free article: PMC2981533] [PubMed: 20705755]

15.

Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodríguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, González JD, Bolufer P, González M, Sanz MA., PETHEMA Group. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005 Oct 20;23(30):7632-40. [PubMed: 16234524]

16.

Lever L, Marks R. Topical retinoid treatment for skin cancer: a review. Skin Pharmacol. 1991;4(3):125-31. [PubMed: 1768423]

17.

Ianhez M, Fleury LF, Miot HA, Bagatin E. Retinoids for prevention and treatment of actinic keratosis. An Bras Dermatol. 2013 Jul-Aug;88(4):585-93. [PMC free article: PMC3760934] [PubMed: 24068130]

18.

Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010 Jun;3(6):39-44. [PMC free article: PMC2921751] [PubMed: 20725550]

19.

Peck GL. Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):829-35. [PubMed: 3534022]

20.

Goldfarb MT, Ellis CN, Voorhees JJ. Topical tretinoin: its use in daily practice to reverse photoageing. Br J Dermatol. 1990 Apr;122 Suppl 35:87-91. [PubMed: 2186791]

21.

Huang P, Chandra V, Rastinejad F. Retinoic acid actions through mammalian nuclear receptors. Chem Rev. 2014 Jan 08;114(1):233-54. [PMC free article: PMC3931982] [PubMed: 24308533]

22.

Digiovanna JJ, Mauro T, Milstone LM, Schmuth M, Toro JR. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther. 2013 Jan-Feb;26(1):26-38. [PMC free article: PMC3884695] [PubMed: 23384018]

23.

Gaston A, Garry RF. Topical vitamin A treatment of recalcitrant common warts. Virol J. 2012 Jan 17;9:21. [PMC free article: PMC3274422] [PubMed: 22251397]

24.

Kang S, Kim KJ, Griffiths CE, Wong TY, Talwar HS, Fisher GJ, Gordon D, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves early stretch marks. Arch Dermatol. 1996 May;132(5):519-26. [PubMed: 8624148]

25.

Maeda Y, Yamaguchi T, Hijikata Y, Tanaka M, Hirase C, Takai S, Morita Y, Sano T, Miyatake J, Tatsumi Y, Kanamaru A. Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol. 2008 Jun;134(6):673-7. [PMC free article: PMC12160709] [PubMed: 18008086]

26.

Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008 Oct;59(4):547-66; quiz 567-8. [PubMed: 18793935]

27.

Kang S. The mechanism of action of topical retinoids. Cutis. 2005 Feb;75(2 Suppl):10-3; discussion 13. [PubMed: 15773538]

28.

Wang ZY. Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia. Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:214-8. [PubMed: 11890109]

29.

Kueh YK, Liew PP, Ho PC, Wu TS. Sublingual administration of all-trans-retinoic acid to a comatose patient with acute promyelocytic leukemia. Ann Pharmacother. 1999 Apr;33(4):503-5. [PubMed: 10332546]

30.

Okumura LM, Baruel Okumura PC, Veroneze C. Administration of all-trans retinoic acid through enteral tubes in acute promyelocytic leukemia: the handling of cytotoxic agents and clinical benefits. Rev Bras Hematol Hemoter. 2017 Jan-Mar;39(1):86-88. [PMC free article: PMC5339370] [PubMed: 28270357]

31.

Abla O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukaemia. Br J Haematol. 2014 Jan;164(1):24-38. [PMC free article: PMC5127390] [PubMed: 24117210]

32.

Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol. 2000 Oct;1:101-6. [PubMed: 11905660]

33.

Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol. 2013 Nov;69(5):762-767. [PubMed: 23953888]

34.

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945-73.e33. [PubMed: 26897386]

35.

Fukuno K, Tsurumi H, Goto H, Oyama M, Tanabashi S, Moriwaki H. Genital ulcers during treatment with ALL-trans retinoic acid for acute promyelocytic leukemia. Leuk Lymphoma. 2003 Nov;44(11):2009-13. [PubMed: 14738157]

36.

Otlewska A, Baran W, Batycka-Baran A. Adverse events related to topical drug treatments for acne vulgaris. Expert Opin Drug Saf. 2020 Apr;19(4):513-521. [PubMed: 32347138]

37.

Zhang X, Zhang H, Chen L, Wang M, Xi J, Liu X, Xie M, Li D, Gulati ES, Gong S, Wang H. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Trials. 2018 Sep 05;19(1):476. [PMC free article: PMC6126003] [PubMed: 30185214]

38.

Williams AL, Pace ND, DeSesso JM. Teratogen update: Topical use and third-generation retinoids. Birth Defects Res. 2020 Sep;112(15):1105-1114. [PubMed: 32643315]

39.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Nov 10, 2020. Retinoids. [PMC free article: PMC547852] [PubMed: 31643883]

40.

Su-Yin A, Wong J, Wiegand T, Olson K. Tretinoin overdose: a first case report. J Med Toxicol. 2009 Jun;5(2):73-5. [PMC free article: PMC3550323] [PubMed: 19415591]

41.

Opel D, Kramer ON, Chevalier M, Bigby M, Albrecht J. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. Br J Dermatol. 2017 Oct;177(4):960-966. [PubMed: 27893168]

42.

McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol. 1992 Dec;87(12):1855-8. [PubMed: 1449157]

43.

Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther. 2008 Aug;33(4):331-8. [PubMed: 18613850]

Disclosure: Athina Yoham declares no relevant financial relationships with ineligible companies.

Disclosure: Damian Casadesus declares no relevant financial relationships with ineligible companies.